PI3K/Akt/mTOR Signaling
PI3K/Akt/mTOR signaling inhibitors are compounds that target the phosphoinositide 3-kinase (PI3K), Akt kinase, and mammalian target of rapamycin (mTOR) pathways. These pathways are critical regulators of cell growth, survival, metabolism, and autophagy, making them key targets in cancer research and metabolic disorders. Inhibiting these pathways can help to control tumor growth and proliferation, offering potential therapeutic strategies for various cancers and other diseases characterized by dysregulated cell signaling. At CymitQuimica, we offer a comprehensive selection of high-quality PI3K/Akt/mTOR inhibitors to support your research in oncology, cellular signaling, and metabolic diseases.
Subcategories of "PI3K/Akt/mTOR Signaling"
- AMPK(158 products)
- ATM/ATR(71 products)
- DNA-PK(51 products)
- EGFR(572 products)
- MELK(7 products)
- PDK(9 products)
- PI3K(242 products)
- S6 Kinase(9 products)
- gsk-3(112 products)
- mTOR(144 products)
Show 2 more subcategories
Found 1038 products of "PI3K/Akt/mTOR Signaling"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BX-320
CAS:<p>BX-320, a PDK1 inhibitor (IC50=30nM), selectively blocks Akt/p70S6K1 phosphorylation, induces apoptosis, and inhibits cancer cell growth.</p>Formula:C23H31BrN8O3Color and Shape:SolidMolecular weight:547.45BEBT-109
CAS:<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Formula:C27H32N8O3Purity:97.26%Color and Shape:SolidMolecular weight:516.6EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formula:C28H33BrN7O2PColor and Shape:SolidMolecular weight:610.49EGFR-IN-61
CAS:<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Formula:C33H37ClN8O3Purity:98%Color and Shape:SolidMolecular weight:629.15EGFR-IN-85
CAS:<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Formula:C26H30N8O2Purity:98%Color and Shape:SolidMolecular weight:486.57JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formula:C22H23BrFN5O2Purity:98%Color and Shape:SolidMolecular weight:488.35PI3K/mTOR Inhibitor-12
CAS:<p>PI3K/mTOR Inhibitor-12: oral, potent, selective; IC50: PI3Kα 0.06 nM, mTOR 3.12 nM; strong antitumor; less liver toxicity.</p>Formula:C27H27F2N9O4SPurity:98%Color and Shape:SolidMolecular weight:611.62Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formula:C25H26ClFN4O4Purity:99.7%Color and Shape:SolidMolecular weight:500.95EGFR/CSC-IN-1
CAS:<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Formula:C54H54Cl2FN7O7S2Purity:98%Color and Shape:SolidMolecular weight:1067.082′-Thioadenosine
CAS:<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Formula:C10H13N5O3SPurity:98%Color and Shape:SolidMolecular weight:283.31DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formula:C28H27F2N7O3Purity:98%Color and Shape:SolidMolecular weight:547.56EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Formula:C34H39ClFN7O2Purity:98%Color and Shape:SolidMolecular weight:632.17GSK-3β inhibitor 8
CAS:<p>GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine</p>Formula:C20H20ClN5OSPurity:98.46%Color and Shape:SolidMolecular weight:413.92EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64AMPK-α1β1γ1 activator 1
CAS:<p>AMPK-α1β1γ1 activator 1 (M1), an acyl glucuronide metabolite derived from an Indole-3-carboxylic Acid-based AMPK activator, selectively activates the β1</p>Formula:C25H24ClNO9Purity:98%Color and Shape:SolidMolecular weight:517.91EGFR-IN-87
CAS:<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Formula:C28H33N7O2Purity:98.64%Color and Shape:SolidMolecular weight:499.61EGFR-IN-1 hydrochloride
CAS:<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Formula:C28H31ClN6O4Purity:99.16%Color and Shape:SolidMolecular weight:551.04BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formula:C24H31N5O4Purity:96.74%Color and Shape:SolidMolecular weight:453.53EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Formula:C23H15ClFN3OS2Purity:98.93%Color and Shape:SolidMolecular weight:467.97Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93Rheb inhibitor NR1
CAS:<p>Rheb inhibitor NR1 is a Rheb inhibitor and selective mTORC1 inhibitor that promotes phosphorylation of S473pAKT.</p>Formula:C25H19BrCl2N2O3SPurity:99.72%Color and Shape:SolidMolecular weight:578.3PI3K-IN-54
CAS:<p>Compound 10w, a substituted pyrazolo[1,5-a]pyrimidinamide compound, is a ZSTK474 analog that shows anticancer activity against HeLa cells.</p>Formula:C20H24F2N8O3Purity:98.15%Color and Shape:SolidMolecular weight:462.45GSK-F1
CAS:<p>GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.</p>Formula:C27H18F5N5O4SPurity:97.03%Color and Shape:SolidMolecular weight:603.52PF-04979064
CAS:<p>PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor(Ki of 0.13 nM and 1.42 nM,respectively).</p>Formula:C24H26N6O3Purity:98.20% - ≥98%Color and Shape:SolidMolecular weight:446.5PKI-402
CAS:<p>PKI-402 is a potent PI3K and mTOR inhibitor. PKI-402 inhibits PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ with IC50s of 2, 3, 7, 14 and 16 nM, respectively.</p>Formula:C29H34N10O3Purity:99.94%Color and Shape:SolidMolecular weight:570.65GSK-3 inhibitor 1
CAS:<p>GSK-3 inhibitor 1 is a GSK-3 inhibitor.</p>Formula:C22H17ClFN5O2Purity:98.42%Color and Shape:SolidMolecular weight:437.85EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formula:C32H23ClF3N7O4Purity:99.51%Color and Shape:SolidMolecular weight:662.02GDC-0349
CAS:<p>GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.</p>Formula:C24H32N6O3Purity:96.00% - 98.17%Color and Shape:SolidMolecular weight:452.55GLPG3312
CAS:<p>GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .</p>Formula:C23H21F2N5O3Purity:98.53%Color and Shape:SolidMolecular weight:453.44EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Formula:C14H11BrN4O2SColor and Shape:SolidMolecular weight:379.23DNA-PK-IN-15
CAS:<p>DNA-PK-IN-15 (compound 6) acts as an inhibitor of DNA-PK, exhibiting an IC50 value of 0.08 nM.</p>Formula:C23H23N9OColor and Shape:SolidMolecular weight:441.49HER2-IN-7
CAS:<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formula:C28H26F3N7O3Color and Shape:SolidMolecular weight:565.55EGFR-IN-160
CAS:<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Formula:C15H12N2O4Color and Shape:SolidMolecular weight:284.27EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Color and Shape:SolidEGFR-IN-147
CAS:<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Formula:C13H13N5OColor and Shape:SolidMolecular weight:255.275EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Formula:C24H15FO3Color and Shape:SolidMolecular weight:370.37EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Formula:C27H25N3O6SColor and Shape:SolidMolecular weight:519.57LAS195319
CAS:<p>LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.</p>Formula:C29H26N10O3SColor and Shape:SolidMolecular weight:594.65EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Formula:C36H44BrN10O3PColor and Shape:SolidMolecular weight:775.68iMDK quarterhydrate
<p>iMDK quarterhydrate, PI3K inhibitor, blocks MDK growth; suppresses NSCLC safely with MEK inhibitor.</p>Formula:C21H15FN2O3SColor and Shape:SolidMolecular weight:380.91ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Formula:C25H27F3N8O2Color and Shape:SolidMolecular weight:528.53EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formula:C31H30FN7OColor and Shape:SolidMolecular weight:535.61Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Formula:C31H33Cl2FN4O5SColor and Shape:SolidMolecular weight:663.59PI3Kδ-IN-23
CAS:<p>PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with an IC50 of 0.27 nM. It binds to PI3Kδ through covalent interaction with Lys779 and plays a significant role in cancer research.</p>Formula:C30H30N6O5Color and Shape:SolidMolecular weight:554.596DNA-PK-IN-6
CAS:<p>DNA-PK-IN-6 inhibits DNA-PKcs, disrupting tumor DNA repair and triggering apoptosis; enhances radiotherapy and targets various tumors (WO2021197159A1).</p>Formula:C19H21N7OColor and Shape:SolidMolecular weight:363.42EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Formula:C26H28ClN3O4Color and Shape:SolidMolecular weight:481.975-Bromo-3-indoxylacetate
CAS:<p>5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.</p>Formula:C10H8BrNO2Color and Shape:SolidMolecular weight:254.08HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Formula:C19H14BrF3N2OColor and Shape:SolidMolecular weight:423.23DNA-PK-IN-8
CAS:<p>DNA-PK-IN-8: Potent, selective oral DNA-PK inhibitor, IC50 = 0.8 nM, boosts anti-cancer effects with Doxorubicin.</p>Formula:C19H22N8O2Color and Shape:SolidMolecular weight:394.43Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formula:C31H36N8O3Color and Shape:SolidMolecular weight:568.669EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Formula:C12H14N4OS2Color and Shape:SolidMolecular weight:294.4Tyrphostin 63
CAS:<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Formula:C10H8N2OColor and Shape:SolidMolecular weight:172.183EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formula:C30H26N8OColor and Shape:SolidMolecular weight:514.58PI3K-IN-27
CAS:<p>PI3K-IN-27 is a potent PI3K inhibitor, relevant for cancer and immune disease research. See patent WO2021233227A1.</p>Formula:C30H26F2N6O2SColor and Shape:SolidMolecular weight:572.63PI3Kβ-IN-1
CAS:<p>PI3Kβ-IN-1 is a selective, orally active PI3Kβ inhibitor (IC50: 2 nM).</p>Formula:C25H14F2N8Color and Shape:SolidMolecular weight:464.43ETP-47037
CAS:<p>ETP-47037: strong PI3Kα inhibitor (IC50: 0.99 nM), also targets PI3Kβ, δ, γ; may protect telomeres.</p>Formula:C20H27N9O3SColor and Shape:SolidMolecular weight:473.55GSK3-IN-9
CAS:<p>GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.</p>Formula:C18H20N4OColor and Shape:SolidMolecular weight:308.378EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Color and Shape:SolidEGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98PI3K-IN-26
CAS:<p>PI3K-IN-26 is an effective PI3K inhibitor. PI3K-IN-26 inhibits the proliferation of SU-DHL-6 cells, IC50= 36 nM.</p>Formula:C21H18N6OSColor and Shape:SolidMolecular weight:402.47EGFR-IN-133
CAS:<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Formula:C27H29F2N7O3Color and Shape:SolidMolecular weight:537.56EGFR-IN-132
CAS:<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Formula:C27H31N7O3Color and Shape:SolidMolecular weight:501.58EGFR-IN-139
CAS:<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Formula:C27H25ClN2O4Color and Shape:SolidMolecular weight:476.951Tarloxotinib bromide
CAS:<p>Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.</p>Formula:C24H24Br2ClN9O3Purity:99.52%Color and Shape:SolidMolecular weight:681.77Vps34-IN-3
<p>Vps34-IN-3 is a potent, selective, and orally bioavailable inhibitor of VPS34 kinase .</p>Formula:C14H20N4O2Color and Shape:SolidMolecular weight:276.33EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formula:C33H28N6O3SColor and Shape:SolidMolecular weight:588.68PI3kδ inhibitor 1
CAS:<p>PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).</p>Formula:C28H33FN6O2Purity:98%Color and Shape:SolidMolecular weight:504.60PI4KIIIbeta-IN-11
CAS:<p>PI4KIIIbeta-IN-11 is a PI4KIIIβ inhibitor (mean pIC50=9.1) that can be used to study diseases caused by RNA viruses and Plasmodium falciparum.</p>Formula:C33H39N7O3Color and Shape:SolidMolecular weight:581.71SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Formula:C22H31ClN4O6Color and Shape:SolidMolecular weight:482.96EGFR-IN-149
CAS:<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formula:C16H15N3OSColor and Shape:SolidMolecular weight:297.375NS-062
CAS:<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Formula:C28H30Cl2F2N6O4Color and Shape:SolidMolecular weight:623.48PF-5177624
CAS:<p>PF-5177624 is a selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells.</p>Formula:C25H25FN8O2Color and Shape:SolidMolecular weight:488.52GSK-3β inhibitor 25
CAS:<p>GSK-3β inhibitor25 (Compound 6h) exhibits weak inhibitory activity against GSK-3β with an IC50 greater than 100 μM.</p>Formula:C16H15NOSColor and Shape:SolidMolecular weight:269.361EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formula:C21H23N3O5Color and Shape:SolidMolecular weight:397.4244-FPBUA
CAS:<p>4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.</p>Formula:C31H23FO7Color and Shape:SolidMolecular weight:526.51DNA-PK-IN-2
CAS:<p>DNA-PK-IN-2 is an inhibitor of the DNA-PK enzyme complex, useful in cancer research.</p>Formula:C20H23N5O3Color and Shape:SolidMolecular weight:381.43HER2-IN-8
CAS:<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Formula:C26H25F2N9O3Color and Shape:SolidMolecular weight:549.53NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formula:C20H16O7Color and Shape:SolidMolecular weight:368.34PD-M6
CAS:<p>PD-M6 is an mTOR PROTAC degrader with a DC50 of 4.8 μM, which facilitates the ubiquitination and degradation of mTOR. It inhibits the proliferation of cancer cell lines HeLa, MCF-7, and HepG2 with IC50 values of 11.3, 2.58, and 3.23 μM, respectively, and induces autophagy. Additionally, PD-M6 specifically targets the degradation of the key protein LAMTOR1 in the mTOR signaling pathway.</p>Formula:C30H39N9O6Color and Shape:SolidMolecular weight:621.69BPI-15086
CAS:<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Formula:C29H33ClN8O4Color and Shape:SolidMolecular weight:593.08BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formula:C18H15N3O2Color and Shape:SolidMolecular weight:305.331GSK3β-IN-2
CAS:<p>GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.</p>Formula:C25H18N4OColor and Shape:SolidMolecular weight:390.437PI3K-IN-37
CAS:<p>PI3K-IN-37 inhibits PI3K α/β/δ (IC50: 6/8/4 nM) and mTOR (IC50: 4 nM).</p>Formula:C25H26N6O2Color and Shape:SolidMolecular weight:442.51DNA-PK-IN-9
<p>DNA-PK-IN-9 (YK6) is a potent DNA-PK inhibitor with an IC50 of 10.47 nM, important in cancer research.</p>Formula:C21H21N5O2Color and Shape:SolidMolecular weight:375.42EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Color and Shape:SolidEGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formula:C30H35FN6O3Color and Shape:SolidMolecular weight:546.64NU5455
CAS:<p>NU5455 is a potent DNA-PKcs inhibitor, oral, boosts doxorubicin in liver tumors, amplifies topoisomerase inhibitors, no adverse effects.</p>Formula:C34H33N3O5SColor and Shape:SolidMolecular weight:595.71EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formula:C16H16N4O2SColor and Shape:SolidMolecular weight:328.39D-69491 hydrochloride
CAS:<p>D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.</p>Formula:C25H26Cl2FN7O3Color and Shape:SolidMolecular weight:562.42GSK3β-IN-1
CAS:<p>GSK3β-IN-1 (compound 1) is an inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 65 nM, and it is utilized in Alzheimer's disease research.</p>Formula:C17H13FN2O4SColor and Shape:SolidMolecular weight:360.36GSK-3β inhibitor 7
<p>GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM).</p>Formula:C27H23BrN4O2SColor and Shape:SolidMolecular weight:547.47EGFR-IN-35
CAS:<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96GSK-3β inhibitor 26
CAS:<p>GSK-3β inhibitor26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. This compound is applicable in research related to cancer, inflammation, and neurodegenerative diseases.</p>Formula:C15H11N3O3Color and Shape:SolidMolecular weight:281.266Pred17
<p>Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.</p>Formula:C27H22BN3OColor and Shape:SolidMolecular weight:415.29EGFR-IN-126
CAS:<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Formula:C28H28BrFN4O3Color and Shape:SolidMolecular weight:567.45SIK2-IN-3
CAS:<p>SIK2-IN-3 is an orally active selective inhibitor of SIK1/2 with IC50 values of 0.128/0.084 μM. It hinders the phosphorylation of CRTC3 and suppresses the production of pro-inflammatory factors in myeloid cells. Additionally, SIK2-IN-3 alleviates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model.</p>Formula:C23H24N6O2Color and Shape:SolidMolecular weight:416.48HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formula:C20H18N4O3SColor and Shape:SolidMolecular weight:394.447GSK-3β inhibitor 6
<p>GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM.</p>Formula:C20H17BrN4Color and Shape:SolidMolecular weight:393.28GSK-3β inhibitor 20
CAS:<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Formula:C22H21N5O2SColor and Shape:SolidMolecular weight:419.50
